RxDoctor Payments Data

Hoke Shirley, MD

Rheumatology · Concord, NHNPI 1962432047

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $364 of the $508 with a category attached, or 71.6%. 7 manufacturers reported payments, led by Pfizer at 35.2% of the total.

$508in general payments, 2019–2025

Across 13 payments — averaging $39.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$179
  • UCB, Inc.$109
  • Johnson & Johnson$100
  • AbbVie$47
  • Radius Health, Inc.$42
  • Amgen$20
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$36472%
  • Education$14528%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$179
UCB, Inc.1$109
Johnson & Johnson1$100
AbbVie3$47
Radius Health, Inc.2$42
Amgen1$20
Novartis1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$508 in reported general payments places this provider in the 55th percentile of 48 rheumatology providers in New Hampshire.

See all rheumatology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$413,534
Medicare patients
682
Services billed
27,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab50$430,479
Enbrel SureclickEtanercept42$324,283
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$240,124
Taltz AutoinjectorIxekizumab31$224,655
Humira(Cf)Adalimumab20$217,775
EnbrelEtanercept23$214,005
RinvoqUpadacitinib29$182,826
XeljanzTofacitinib Citrate29$165,206
Xeljanz XrTofacitinib Citrate29$162,467
OtezlaApremilast25$133,527
Teriparatide65$119,500
HumiraAdalimumab11$97,350
OxycontinOxycodone Hcl65$72,146
Cimzia (2 Pack)Certolizumab Pegol11$62,513
Fentanyl170$22,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Rinvoq, Humira, Savella$47$514,48775 claims
AmgenEnbrel, Otezla$20$347,53248 claims
PfizerXeljanz$179$165,20629 claims
UCB, Inc.Cimzia (2 Pack)$109$62,51311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 48 rheumatology providers in New Hampshire.

Other rheumatology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →